Healthcare & Pharma
Electronic health records, clinical trial data, medical imaging, genomic sequences, and patient interaction logs — healthcare generates more structured, high-value training data than any other industry.
Market Snapshot
$4.2B market by 2027
Market Size: $4.2B
CAGR: 24.3%
$4.2B market by 2027 in annual AI data licensing value, growing at 24.3% annually.
Key Metrics
AI Training Data Market (Healthcare)
$423M
2024 market size for healthcare AI training datasets, projected to reach $1.47B by 2030 (Grand View Research)
Growth Rate
22.9%
CAGR for healthcare AI training data from 2025-2030, outpacing the overall AI data market at 16.5%
Medical Imaging Share
43.2%
Image and video data dominated the healthcare AI training market in 2024, led by radiology and pathology datasets
Broader Healthcare AI Market
$4.2B
Total AI in healthcare market encompassing data, applications, and infrastructure (Fortune Business Insights)
Real-World Data Deals
$2.6B+
Cumulative value of healthcare data licensing and acquisition deals closed in 2024-2025 across top 10 transactions
De-identified Records Available
380M+
Estimated total de-identified patient records across major US health data aggregators including Flatiron, Tempus, and Optum
Clinical Trial Data Premium
3-5x
Price premium that annotated clinical trial datasets command versus standard EHR extracts
Genomic Dataset Growth
31.4%
Year-over-year growth in demand for annotated genomic and multi-omic datasets for AI model training
The Healthcare Data Opportunity
The Healthcare & Pharmadata opportunity.
Healthcare generates more high-value training data per dollar than any other vertical in the AI economy. Every patient encounter, diagnostic image, lab result, and clinical note creates structured and unstructured data that AI companies desperately need to build models for drug discovery, clinical decision support, diagnostic imaging, and population health management.
The global AI training dataset market for healthcare was valued at $423 million in 2024 and is projected to reach $1.47 billion by 2030, growing at a 22.9% CAGR. This growth is driven by the convergence of precision medicine, genomics, and foundation models that require massive volumes of annotated clinical data to achieve diagnostic-grade accuracy.
What makes healthcare data uniquely valuable is its scarcity and regulatory complexity. HIPAA de-identification requirements, IRB approval processes, and institutional data governance frameworks create significant barriers to entry. Organizations that have already navigated these compliance requirements and built clean, structured datasets sit on assets that command premium pricing in the AI training data market.
The shift from fee-for-service to value-based care has also created a secondary market for real-world evidence (RWE) data. Pharmaceutical companies, CROs, and health systems are licensing de-identified EHR data, claims data, and genomic datasets to power everything from clinical trial design to post-market surveillance algorithms.
Data Types
What Healthcare & Pharma
generates.
Every healthcare & pharma organization generates valuable datasets. These are the formats AI companies are actively purchasing.
Who's Buying
Who buyshealthcare & pharma data.
Real Deals
Healthcare & Pharmadeals that
closed.closed.
$1.9B
Landmark acquisition of oncology EHR and real-world evidence platform. Flatiron's network spans 280+ community oncology practices and 800+ clinical sites generating structured cancer treatment data.
$200M
Multi-year data licensing agreement announced April 2025. AstraZeneca gains access to Tempus's vast library of de-identified genomic and clinical data for drug development and clinical trial optimization.
$600M
Acquisition finalized February 2025. Brings AI-driven whole-genome analysis and hereditary cancer testing capabilities, adding millions of genetic test records to Tempus's data platform.
$560M
Imaging and AI deal signed March 2025 with Alberta Cancer Foundation. Includes $124M for two AI centers of excellence focused on diagnostic imaging AI training.
$81.2M
August 2025 acquisition of computational pathology AI company. PAIGE's foundation models trained on millions of whole-slide images integrated into Tempus diagnostic platform.
$95M
2024 acquisition ($70M in shares + $25M milestones) bringing AI-driven minimal residual disease detection and whole-genome sequencing capabilities.
AI Use Cases
How AI useshealthcare & pharma data.
Diagnostic Imaging AI
Training convolutional neural networks and vision transformers to detect tumors, fractures, and pathologies in X-rays, CTs, MRIs, and mammograms. Requires millions of annotated DICOM images with radiologist ground truth labels.
Drug Discovery & Molecular Modeling
Foundation models like AlphaFold use protein structure data and molecular interaction datasets to predict drug-target binding, reducing preclinical timelines from years to months.
Clinical Decision Support
NLP models trained on millions of clinical notes, discharge summaries, and treatment protocols to surface evidence-based treatment recommendations at point of care.
Precision Oncology
Genomic profiling models match tumor mutation signatures against treatment response databases to recommend targeted therapies. Tempus and Foundation Medicine lead this market.
Clinical Trial Matching
AI models trained on EHR data, eligibility criteria, and outcome data to automatically identify and recruit eligible patients, reducing enrollment timelines by 30-50%.
Predictive Population Health
Machine learning on claims data, SDOH factors, and utilization patterns to predict hospital readmissions, disease progression, and resource allocation needs.
Medical Coding Automation
NLP models trained on millions of coded encounters to automate ICD-10, CPT, and DRG assignment, reducing coding backlogs and improving revenue cycle accuracy.
Pathology & Histology AI
Computer vision models analyzing digitized tissue slides to grade cancers, identify biomarkers, and quantify treatment response with superhuman precision.
Healthcare Data Pricing
Healthcare data commands the highest per-record pricing in the AI training data market due to regulatory compliance costs, annotation complexity, and scarcity. Pricing varies dramatically based on data type, de-identification level, annotation depth, and exclusivity terms.
Clinical trial datasets with structured outcomes data trade at 3-5x the price of standard EHR extracts. Annotated medical imaging datasets command premium pricing due to the cost of expert radiologist and pathologist annotation, which typically runs $50-200 per image for detailed segmentation labels.
De-identified EHR Records
$0.50 - $5.00 / record
Structured patient records with demographics, diagnoses, procedures, and medications. Price depends on longitudinal depth and linkage to claims or outcomes data.
Annotated Medical Images
$15 - $200 / image
Expert-annotated radiology or pathology images with segmentation masks, bounding boxes, and diagnostic labels. Whole-slide pathology images at the higher end.
Genomic Sequences
$50 - $500 / sample
Whole-genome or whole-exome sequences with variant calling and phenotype annotations. Multi-omic panels (genomic + transcriptomic + proteomic) command top prices.
Claims & Billing Data
$0.10 - $1.00 / record
Insurance claims with ICD-10, CPT codes, costs, and outcomes. Large longitudinal panels covering 5+ years command premium pricing.
Clinical Trial Datasets
$500 - $5,000 / patient
Structured trial data with endpoints, adverse events, and biomarker panels. Phase III oncology trials at the top of the range due to annotation depth.
Clinical Notes (NLP-ready)
$2 - $20 / note
De-identified physician notes, discharge summaries, and operative reports prepared for NLP model training with entity annotations.
Regulatory Framework
Regulatorylandscape.
Healthcare data monetization operates within the most complex regulatory environment of any industry vertical. The intersection of patient privacy, research ethics, and commercial licensing creates multi-layered compliance requirements that simultaneously restrict supply and increase the value of properly compliant datasets.
Organizations that have invested in robust de-identification pipelines, data governance frameworks, and IRB-approved data sharing protocols possess a significant competitive advantage. The cost of building compliant data infrastructure typically runs $500K-$2M, creating a natural moat around established data providers.
HIPAA (Health Insurance Portability and Accountability Act)
United States
Requires Safe Harbor or Expert Determination de-identification for any commercial use. 18 specified identifiers must be removed or generalized. Covered entities must execute Business Associate Agreements (BAAs) with data recipients.
HITECH Act
United States
Extends HIPAA enforcement to business associates and increases penalties for data breaches. Requires breach notification within 60 days. Penalties range from $100 to $50,000 per violation, up to $1.5M annually per category.
EU GDPR (General Data Protection Regulation)
European Union
Health data classified as 'special category' requiring explicit consent or approved research basis. The EU AI Act (2025) adds mandatory training data provenance documentation for high-risk health AI systems.
FDA 21 CFR Part 11
United States
Electronic records used in clinical trials or regulatory submissions must meet integrity, audit trail, and validation requirements. Applies to AI/ML-derived diagnostics seeking FDA clearance.
Common Rule (45 CFR 46)
United States
Governs human subjects research including secondary use of clinical data. IRB approval required for research use. Exemptions exist for de-identified data but interpretations vary by institution.
State Privacy Laws (CCPA, CMIA, etc.)
US States
California CMIA provides additional protections beyond HIPAA for medical information. Washington My Health My Data Act covers consumer health data not covered by HIPAA. 15+ states have enacted health data-specific provisions.
Get yourhealthcare & pharmadata
appraised.
Your healthcare & pharma data is exactly what AI companies need for model training. We handle the valuation, compliance, and buyer matching.
Get Your Healthcare & Pharma Data Appraised